Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXLNYSE:BHVNNASDAQ:PTGXNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$9.36-2.1%$9.03$3.25▼$14.44$796.20M0.941.23 million shs1.05 million shsBHVNBiohaven$28.85-3.4%$35.50$26.80▼$57.07$2.94B1.271.05 million shs821,206 shsPTGXProtagonist Therapeutics$49.56-2.9%$42.04$24.22▼$60.60$3.04B2.34757,611 shs881,894 shsSRRKScholar Rock$32.16-3.4%$38.15$6.76▼$46.98$3.04B0.591.15 million shs1.22 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences-2.09%-4.88%+13.32%-25.48%+93.39%BHVNBiohaven-3.20%+0.02%-18.65%-20.80%-48.77%PTGXProtagonist Therapeutics-2.92%-8.81%+37.67%+25.44%+77.00%SRRKScholar Rock-3.37%-5.33%-13.46%-29.67%+114.40%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.7915 of 5 stars3.70.00.04.73.10.80.6BHVNBiohaven3.9108 of 5 stars4.53.00.00.02.14.20.6PTGXProtagonist Therapeutics3.6893 of 5 stars4.51.00.00.03.52.51.3SRRKScholar Rock4.076 of 5 stars3.60.00.04.42.83.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00370.09% UpsideBHVNBiohaven 3.07Buy$62.77117.61% UpsidePTGXProtagonist Therapeutics 3.00Buy$62.5626.22% UpsideSRRKScholar Rock 3.14Buy$40.8627.04% UpsideCurrent Analyst Ratings BreakdownLatest AVXL, PTGX, SRRK, and BHVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/20/2025BHVNBiohavenDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.003/17/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/11/2025PTGXProtagonist TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.003/11/2025PTGXProtagonist TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $76.003/11/2025PTGXProtagonist TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$62.00 ➝ $72.003/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $54.003/7/2025BHVNBiohavenMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$69.00 ➝ $63.003/5/2025BHVNBiohavenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$72.00 ➝ $68.003/4/2025BHVNBiohavenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $54.003/4/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$61.00 ➝ $61.00(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ABHVNBiohavenN/AN/AN/AN/A$5.34 per shareN/APTGXProtagonist Therapeutics$434.43M7.00N/AN/A$5.84 per share8.49SRRKScholar Rock$33.19M91.74N/AN/A$3.12 per share10.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%5/8/2025 (Estimated)BHVNBiohaven-$408.17M-$9.39N/AN/AN/AN/A-225.12%-158.89%5/8/2025 (Estimated)PTGXProtagonist Therapeutics-$78.96M$4.2018.63N/AN/A52.76%34.68%30.98%5/6/2025 (Estimated)SRRKScholar Rock-$165.79M-$2.45N/AN/AN/AN/A-145.60%-91.83%5/6/2025 (Estimated)Latest AVXL, PTGX, SRRK, and BHVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/3/2025Q4 2024BHVNBiohaven-$1.56-$1.85-$0.29-$1.85$100.00 millionN/A2/21/2025Q4 2024PTGXProtagonist Therapeutics-$0.09$1.98+$2.07$1.98$56.65 million$170.64 million2/12/2025Q1 2025AVXLAnavex Life Sciences-$0.17-$0.14+$0.03-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A9.459.45BHVNBiohavenN/A2.892.89PTGXProtagonist TherapeuticsN/A10.6910.70SRRKScholar Rock0.633.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%BHVNBiohaven88.78%PTGXProtagonist Therapeutics98.63%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.00%BHVNBiohaven16.00%PTGXProtagonist Therapeutics5.40%SRRKScholar Rock19.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.06 million75.71 millionOptionableBHVNBiohaven239102.07 million84.94 millionOptionablePTGXProtagonist Therapeutics12061.38 million56.38 millionOptionableSRRKScholar Rock14094.68 million75.64 millionOptionableAVXL, PTGX, SRRK, and BHVN HeadlinesRecent News About These CompaniesInsider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells 6,500 Shares of StockMarch 26 at 10:25 PM | marketbeat.comScholar Rock (NASDAQ:SRRK) Receives "Outperform" Rating from WedbushMarch 26 at 10:08 PM | marketbeat.comSwiss National Bank Boosts Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 25 at 3:35 AM | marketbeat.comVictory Capital Management Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 23, 2025 | marketbeat.comAlphaQuest LLC Sells 34,414 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)March 21, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Director Katie Peng Sells 1,006 SharesMarch 20, 2025 | marketbeat.com54,717 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Bought by Proficio Capital Partners LLCMarch 19, 2025 | marketbeat.comWedbush Reiterates Outperform Rating for Scholar Rock (NASDAQ:SRRK)March 19, 2025 | americanbankingnews.comWedbush Reaffirms "Outperform" Rating for Scholar Rock (NASDAQ:SRRK)March 18, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Buys Shares of 28,599 Scholar Rock Holding Co. (NASDAQ:SRRK)March 18, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 119,616 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)March 18, 2025 | marketbeat.comTD Cowen Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)March 17, 2025 | markets.businessinsider.comScholar Rock announces Phase 3 SAPPHIRE dataMarch 16, 2025 | markets.businessinsider.comScholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific ConferenceMarch 16, 2025 | businesswire.comScholar Rock issues equity awards to new employeesMarch 16, 2025 | investing.comBank of New York Mellon Corp Has $8.97 Million Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 15, 2025 | marketbeat.comEdward H. Myles Sells 142,292 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) StockMarch 13, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Trading Up 6.1% - Here's WhyMarch 13, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) CFO Sells $5,068,441.04 in StockMarch 13, 2025 | insidertrades.comScholar Rock Holding Co. (NASDAQ:SRRK) Given Average Recommendation of "Buy" by BrokeragesMarch 13, 2025 | marketbeat.comScholar Rock (SRRK) to Release Earnings on TuesdayMarch 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVXL, PTGX, SRRK, and BHVN Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$9.36 -0.20 (-2.09%) Closing price 03/26/2025 04:00 PM EasternExtended Trading$9.34 -0.02 (-0.21%) As of 08:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Biohaven NYSE:BHVN$28.84 -1.03 (-3.43%) Closing price 03/26/2025 03:58 PM EasternExtended Trading$30.30 +1.45 (+5.04%) As of 09:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Protagonist Therapeutics NASDAQ:PTGX$49.56 -1.49 (-2.92%) Closing price 03/26/2025 04:00 PM EasternExtended Trading$49.54 -0.02 (-0.03%) As of 03/26/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Scholar Rock NASDAQ:SRRK$32.16 -1.12 (-3.37%) Closing price 03/26/2025 04:00 PM EasternExtended Trading$32.16 +0.01 (+0.02%) As of 08:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Maybe It’s Time to Buy Some GameStop Stock Is Alphabet Too Cheap to Ignore After Its Recent Correction? Qualcomm Stock Is Coiling for a Breakout Tesla Stock: Has the Mother of All Comebacks Begun? Energy Transfer: Powering Data With Dividends and Diversification Advanced Micro Devices Can Double in Price: Here’s Why Palantir Setting Up to Be a Big Winner With New Defense Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
